<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635826</url>
  </required_header>
  <id_info>
    <org_study_id>300006362</org_study_id>
    <nct_id>NCT04635826</nct_id>
  </id_info>
  <brief_title>The Role of Expectancy for Cognitive Enhancement in College Students Using Prescription Stimulants Nonmedically</brief_title>
  <official_title>The Role of Expectancy for Cognitive Enhancement in College Students Using Prescription Stimulants Nonmedically</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to evaluate the interaction between expectations of receiving stimulants,&#xD;
      neurophysiological activity and enhancement of cognitive performance using fMRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will then be randomized in a balanced placebo design (BPD) crossing medication&#xD;
      (10 mg of mixed amphetamine salts vs placebo) and expectancy (told active medication vs&#xD;
      placebo medication), resulting in 4 different conditions 1) mixed amphetamine salts/told&#xD;
      stimulant medication; 2) placebo/told stimulant medication; 3) mixed amphetamine salts/told&#xD;
      placebo; and 4) placebo/told placebo). Participants will be assigned to four scanning&#xD;
      sessions scheduled one week apart and will experience each condition once counterbalanced&#xD;
      across participants. Participants will be administered cognitive tasks in and out of the&#xD;
      scanner to determine the effects of medication vs expectancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 X 2, within-subjects, balanced placebo design</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>How expectancy will affect cognitive performance</measure>
    <time_frame>120 minutes</time_frame>
    <description>Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. The main outcome measure is how the expectancy of stimulants will affect cognitive performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The impact that stimulants vs. placebo have on the neural circuitry</measure>
    <time_frame>120 minutes</time_frame>
    <description>Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. This outcome measure is to determine the impact stimulant administration and expectancy of stimulants have on the neural circuitry that supports sustained attention, inhibitory control, and verbal memory processes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine whether stimulant administration and expectancy for stimulants modify the functional connectivity of brain networks</measure>
    <time_frame>120 minutes</time_frame>
    <description>Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. This outcome measure is to determine whether stimulant administration and expectancy for stimulants modify the functional connectivity of brain networks that support cognitive processes under investigation.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prescription Stimulants</condition>
  <condition>Expectations</condition>
  <condition>Deception</condition>
  <arm_group>
    <arm_group_label>Adderall/Truth</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving Adderall and will actually be administered Adderall.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall/Deception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving Adderall and will actually be administered placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Truth</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be told they are receiving placebo and will actually be administered placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Deception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving placebo and will actually be administered Adderall</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall 10Mg Tablet</intervention_name>
    <description>Participants will be administered Adderall</description>
    <arm_group_label>Adderall/Truth</arm_group_label>
    <arm_group_label>Placebo/Deception</arm_group_label>
    <other_name>Adderall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be administered placebo</description>
    <arm_group_label>Adderall/Deception</arm_group_label>
    <arm_group_label>Placebo/Truth</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-30 years old&#xD;
&#xD;
          -  enrolled as a student at UAB or local college/university&#xD;
&#xD;
          -  if female, willing to use adequate birth control or abstain from sexual activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current or prior head injury&#xD;
&#xD;
          -  current or prior psychiatric diagnosis (including ADHD)&#xD;
&#xD;
          -  neurological disorder or stroke, hypertension, history of blood or circulation&#xD;
             disorders (e.g., anemia or sickle-cell), diabetes, brain or spinal abnormalities&#xD;
&#xD;
          -  blood pressure more than 130 systolic and 80 diastolic&#xD;
&#xD;
          -  heart rate more than 100 beats per minute&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  current illicit substance use as well as nicotine use&#xD;
&#xD;
          -  Alcohol or cannabis use that meets DSM-5 criteria for an alcohol or cannabis use&#xD;
             disorder&#xD;
&#xD;
          -  Inability to abstain from alcohol or cannabis the night before and day of the scanning&#xD;
             session&#xD;
&#xD;
          -  Inability to reduce caffeine intake to less than 100 mg on testing days in heavy&#xD;
             caffeine users&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  hearing impairment&#xD;
&#xD;
          -  vision impairment that cannot be corrected by MRI-compatible lenses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Cropsey, PsyD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Knight, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keith Chichester, M.A.</last_name>
    <phone>205-975-7809</phone>
    <email>kchichester@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofia Mildrum Chana, B.A.</last_name>
    <phone>205-975-7809</phone>
    <email>smildrumchana@uab.edu</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Karen Cropsey</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

